Sapient Capital LLC Reduces Position in Pfizer Inc. $PFE

Sapient Capital LLC decreased its holdings in Pfizer Inc. (NYSE:PFE) by 4.8% in the first quarter, Holdings Channel reports. The fund owned 451,838 shares of the biopharmaceutical company’s stock after selling 22,939 shares during the period. Sapient Capital LLC’s holdings in Pfizer were worth $12,685,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $26,000. YANKCOM Partnership acquired a new position in Pfizer during the fourth quarter worth $28,000. HFM Investment Advisors LLC grew its holdings in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares in the last quarter. Evolution Wealth Management Inc. increased its stake in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares during the last quarter. Finally, Abound Financial LLC purchased a new position in shares of Pfizer during the 4th quarter worth $31,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 vitiligo data: Pfizer reported that oral LITFULO significantly improved skin repigmentation in two late-stage trials for nonsegmental vitiligo. The results support planned regulatory filings and could create a new growth opportunity for the company. Reuters LITFULO vitiligo trial article
• Positive Sentiment: Updated COVID vaccine approved in Europe: The European Commission authorized Pfizer and BioNTech’s XFG-adapted vaccine for the 2026–2027 season across the European Union. The approval enables production and advance supply, although seasonal COVID demand remains difficult to forecast. EU approval article
• Positive Sentiment: Value appeal and estimates: Investor commentary highlights Pfizer’s roughly 6.8% dividend yield and inexpensive earnings valuation, while Erste Group reportedly raised its FY2027 EPS estimate. These factors may attract income and value-focused investors. Pfizer valuation article
• Neutral Sentiment: Upcoming earnings focus: Analysts are watching Pfizer’s second-quarter revenue, adjusted earnings, product sales and full-year outlook. The available reports are previews rather than an announcement of actual quarterly results, so earnings remain a near-term catalyst. Pfizer Q2 earnings preview
• Negative Sentiment: Growth concerns remain: Pfizer’s valuation reflects investor skepticism about post-pandemic revenue, a comparatively modest growth profile and execution risks surrounding its pipeline. Its obesity-drug candidate is promising but still late-stage and faces powerful competition from Eli Lilly and Novo Nordisk, limiting any immediate earnings benefit. Pfizer earnings preview and valuation article

Pfizer Stock Up 0.4%

Shares of PFE opened at $25.10 on Monday. The stock has a market capitalization of $143.06 billion, a PE ratio of 19.16 and a beta of 0.34. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company’s 50-day simple moving average is $25.04 and its 200-day simple moving average is $26.16.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is 131.30%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PFE. Citigroup upped their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and decreased their target price for the company from $32.00 to $28.00 in a report on Monday, July 6th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Guggenheim decreased their price objective on Pfizer from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $28.50.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.